Lymphoma - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Monoclonal Antibody Therapy for Treatment-Resistant Blood Cancers
(Posted: 03/29/2005, Updated: 05/16/2007) - This phase I dose-escalation study is investigating safety and tolerability of siplizumab, and will determine the maximum dose that can be given to patients with CD2-positive lymphoproliferative disease.
- Romidepsin for T-Cell Lymphoma
(Posted: 01/13/2004, Updated: 05/01/2007) - With this trial, researchers are seeking to determine whether romidepsin (depsipeptide, FR901228), a histone deacetylase inhibitor, can help bring about remission in patients with T-cell lymphoma.
- Treating Adult T-cell Leukemia/Lymphoma
(Posted: 11/07/2006) - In this clinical trial, researchers will use denileukin diftitox (Ontak), a genetically engineered protein that combines segments of interleukin-2 and diphtheria toxin, to treat patients with adult T cell leukemia/lymphoma that shows a receptor protein for interleukin-2.
- Studying Chronic Graft-versus-Host Disease
(Posted: 07/18/2006) - In this study, researchers are interested in determining the natural history of chronic graft-versus-host disease and assessing biological factors that may predict outcomes associated with it.
- Targeted Treatment for Cutaneous T-Cell Lymphoma
(Posted: 02/07/2006) - In this clinical trial, researchers are testing the effectiveness of an immunotoxin called LMB-2 in killing cutaneous T-cell lymphoma cells. LMB-2 is a monoclonal antibody fragment attached to a bacterial toxin.